Spun out: Companies born at Wolfson

The Wolfson Institute for Biomedical Research was established to bring together the best of industry and academia, so it isn't surprising that several spinout companies have emerged from its walls in recent years.

By Stephen Pincock

Related Articles

Watching Wolfson

  • Ark Therapeutics (1997) has several products in late-stage clinical development, including a gene-based therapy for glioma with orphan drug status in the European Union, and a treatment for cachexia in Phase II trials.

  • Arrow Therapeutics (1998) uses genome-based approaches for discovery of novel anti-infective targets and drugs. AstraZeneca recently acquired the company.

  • Cerexus (1997) is a joint venture between WIBR and the neuroscience biotechnology company, Cerebrus. When Vanguard Medica acquired Cerebrus in 1999, Cerexus underwent a trade sale to the combined company, Vernalis.

  • NCE Discovery (2001) offered medicinal chemistry to biotech firms. This year, NCE merged with another University College London spinout company to...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?